Q4 2026 Cardinal Health, Inc Earnings Call Transcript
Key Points
- Strong fourth quarter and fiscal 2026 results with enterprise operating earnings and EPS growing 30% and 40% respectively, driven by broad-based demand.
- Pharmaceutical and Specialty Solutions segment delivered 21% profit growth, supported by robust brand and specialty portfolios and positive generics performance.
- Global Medical Products and Distribution segment showed significant profit improvement, growing to $150 million, reflecting solid operational execution and the GMPD improvement plan.
- Other growth businesses (at-Home Solutions, Nuclear and Precision Health, OptiFreight Logistics) collectively delivered 14% profit growth, with strong secular tailwinds and successful integration of acquisitions like ADS.
- Generated $5 billion in adjusted free cash flow for fiscal 2026, returned $1.35 billion to shareholders via buybacks, and increased share repurchase authorization by $5 billion, signaling confidence in future cash generation.
- Fiscal 2027 guidance implies 13-15% EPS growth, above the long-term 12-14% target, with continued momentum across all segments and contributions from recent M&A.
- Fiscal 2027 guidance assumes a more normalized demand environment, not the outsized growth experienced in fiscal 2026, which could temper revenue growth.
- Pharmaceutical segment faces headwinds from IRA price changes and annualization of 2026 WAC reductions, impacting revenue growth.
- GMPD segment profit guidance is modest at $200-220 million, with Q1 fiscal 2027 expected to be roughly half of Q1 fiscal 2026 due to foreign currency and distributor purchase timing.
- Potential protracted conflicts in Iran could move GMPD profit to the lower end of guidance due to rising fuel and commodity costs.
- The company continues to incur costs from tariffs that replaced IEEPA, and the $100 million tariff refund is nonrecurring, creating a challenging comparison for future periods.
- SG&A expenses grew 9.5% in the quarter, driven by investments in automation, technology, and acquisitions, which could pressure margins if not offset by revenue growth.
Hello, everyone. Thank you for joining us, and welcome to Cardinal Health, Inc fourth quarter fiscal year 2026 earnings release. (Operator Instructions)
I will now hand the conference over to David Frost, Vice President of Investor Relations. Please go ahead.
Good morning. Welcome to Cardinal Health's Fourth Quarter Fiscal 2026 Earnings Conference Call, and thank you for joining us. With me today are Cardinal Health's CEO, Jason Hollar; and our CFO, Aaron Alt. You can find this morning's earnings press release and investor presentation on the Investor Relations section of our website at ir.cardinalhealth.com.
Since we will be making forward-looking statements today, let me remind you that the matters addressed in these statements are subject to risks and uncertainties that could cause our actual results to differ materially from those projected or implied. Please refer to our SEC filings and the forward-looking statement slide at the beginning of our presentation for a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
